Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.
Thymoma Type B3|Thymic Carcinoma
DRUG: Nivolumab
Progression Free Survival Rate (PFSR) at month 6, The Progression Free Survival Rate (PFSR) analysis will be performed at month 6
Progression Free Survival (PFS), 32 months after first patient in|Overall Survival (OS), 32 months after first patient in|Toxicity according CTCAE version 4.03, This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, for adverse event reporting., 32 months after first patient in|Overall Response Rate (ORR), Overall Response Rate (ORR) will be measured according to RECIST 1.1, 32 months after first patient in|Disease Control Rate (DCR), 32 months after first patient in|Duration of response, 32 months after first patient in
The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.